Brady W. Dougan Sells 352,112 Shares of Humacyte, Inc. (NASDAQ:HUMA) Stock

Humacyte, Inc. (NASDAQ:HUMA) Director Brady W. Dougan sold 352,112 shares of the stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $6.35, for a total transaction of $2,235,911.20. Following the transaction, the director now directly owns 3,677,262 shares in the company, valued at approximately $23,350,613.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Humacyte Trading Down 1.6 %

Shares of NASDAQ HUMA opened at $6.05 on Friday. The company has a quick ratio of 8.37, a current ratio of 8.37 and a debt-to-equity ratio of 0.61. The stock’s 50 day moving average price is $6.86 and its two-hundred day moving average price is $5.45. Humacyte, Inc. has a 52-week low of $1.96 and a 52-week high of $9.97. The stock has a market capitalization of $720.46 million, a P/E ratio of -6.05 and a beta of 1.52.

Institutional Investors Weigh In On Humacyte

Institutional investors and hedge funds have recently made changes to their positions in the company. Victory Capital Management Inc. acquired a new position in Humacyte in the fourth quarter worth $29,000. Kovitz Investment Group Partners LLC bought a new position in shares of Humacyte in the 4th quarter worth about $35,000. Tower Research Capital LLC TRC boosted its holdings in shares of Humacyte by 261.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,989 shares of the company’s stock valued at $26,000 after buying an additional 6,504 shares during the period. China Universal Asset Management Co. Ltd. grew its position in shares of Humacyte by 65.9% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 19,883 shares of the company’s stock valued at $62,000 after buying an additional 7,897 shares during the last quarter. Finally, Hartline Investment Corp acquired a new stake in Humacyte during the first quarter worth about $70,000. 44.71% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $7.00 price objective on shares of Humacyte in a research note on Tuesday, July 2nd. Benchmark restated a “buy” rating and set a $15.00 target price on shares of Humacyte in a research note on Monday, August 12th. Finally, BTIG Research lifted their price target on shares of Humacyte from $8.00 to $11.00 and gave the stock a “buy” rating in a research note on Monday, July 15th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $8.60.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.